Intensity Therapeutics Inc. (NASDAQ:INTS) Receives $37.50 Average Price Target from Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has been assigned an average recommendation of “Moderate Buy” from the four brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $37.50.

A number of analysts have recently weighed in on the stock. Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Freedom Capital raised shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th. Weiss Ratings downgraded shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Finally, Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th.

Intensity Therapeutics Price Performance

INTS stock opened at $4.75 on Friday. The company has a market cap of $12.82 million, a PE ratio of -0.83 and a beta of 2.78. The business has a 50-day simple moving average of $4.35 and a 200 day simple moving average of $6.34. Intensity Therapeutics has a 52 week low of $3.51 and a 52 week high of $43.50. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12. Sell-side analysts anticipate that Intensity Therapeutics will post -2.7 EPS for the current fiscal year.

Institutional Trading of Intensity Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of INTS. Jane Street Group LLC acquired a new stake in Intensity Therapeutics in the fourth quarter valued at about $26,000. Corient Private Wealth LLC bought a new position in shares of Intensity Therapeutics in the fourth quarter worth about $41,000. State Street Corp lifted its holdings in shares of Intensity Therapeutics by 839.3% in the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares during the last quarter. Legacy Advisors LLC acquired a new stake in shares of Intensity Therapeutics in the 4th quarter valued at approximately $63,000. Finally, Mesirow Financial Investment Management Inc. boosted its stake in shares of Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares in the last quarter. 3.74% of the stock is currently owned by institutional investors.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.